The pH-dependent association with cancer cells of tunable functionalized lipid vesicles with encapsulated doxorubicin for high cell-kill selectivity

Biomaterials

Volumn 31, Issue 15, 2010, Pages 4409-4416

  Karve, Shrirang ^a   Bandekar, Amey ^a   Ali, Md R ^a   Sofou, Stavroula ^a  

^a POLYTECHNIC UNIVERSITY   (United States)

Author keywords

Chemotherapy; Liposomes; Targeted liposomal chemotherapy

Indexed keywords

ACIDIC PH; BLOOD STREAMS; BURST RELEASE; CANCER CELLS; DOXORUBICIN; ENDOSOMAL PH; EXTRACELLULAR PH; FUNCTIONALIZED; HETEROGENEOUS MEMBRANES; LIPID VESICLES; PH GRADIENTS; PH-DEPENDENT; PROOF OF CONCEPT; TARGETED LIPOSOMAL CHEMOTHERAPY;

BLOOD; CHEMOTHERAPY; LIGANDS; LIPOSOMES; PHOSPHOLIPIDS; SURFACE TOPOGRAPHY; TUMORS;

CELLS;

DOXORUBICIN; LIGAND; LIPOSOME;

ACIDITY; ARTICLE; BINDING AFFINITY; BLOOD PH; CANCER CELL; CANCER CELL DESTRUCTION; CELL KILLING; CELL PH; CIRCULATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SELECTIVITY; ENCAPSULATION; ENDOCYTOSIS; ENDOSOME; HUMAN; HUMAN CELL; LIPID VESICLE; PH; PRIORITY JOURNAL; SURFACE PROPERTY;

ANTIBIOTICS, ANTINEOPLASTIC; CALORIMETRY, DIFFERENTIAL SCANNING; CELL LINE, TUMOR; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; HYDROGEN-ION CONCENTRATION; LIPIDS; MATERIALS TESTING; MODELS, MOLECULAR;

EID: 77949653038     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.01.064     Document Type: Article

References (39)

1. Service R.F. Nanotechnology takes aim at cancer. Science 2005, 310:1132-1134.
2. Park J.W., Benz C.C., Martin F.J. Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol 2004, 31(Suppl. 13):196-205.
3. Park J.W., Hong K., Carter P., Asgari H., Guo L.Y., Keller G.A., et al. Development of anti-p185HER2 immunoliposomes for cancer therapy. PNAS 1995, 92(5):1327-1331.
4. Park J.W., Hong K., Kirpotin D.B., Colbern G., Shalaby R., Baselga J., et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 2002, 8(4):1172-1181.
5. Kirpotin D.B., Drummond D.C., Shao Y., Shalaby M.R., Hong K., Nielsen U.B., et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 2006, 66(13):6732-6740.
6. Miller C.R., Bondurant B., McLean S.D., McGovern K.A., O'Brien D.F. Liposome-cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes. Biochemistry 1998, 37:12875-12883.
7. deFazio A., Chiew Y.E., Sini R.L., Janes P.W. Sutherland RL. Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines. Int J Cancer 2000, 87(4):487-498.
8. Kirpotin D.B., Park J.W., Hong S.K., Zalipsky S., Li W.-L., Carter P., et al. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry 1997, 36:66-75.
9. HER2: basic research, prognosis and therapy 2000, IOS Press, Amsterdam. Y. Yarden (Ed.).
10. Allen T.M. Ligand-targeted therapeutics in anticancer therapy. Nat Cancer Rev 2002, 2:750-763.
11. Ishida T., Kirchmeier M.J., Moase E.H., Zalipsky S., Allen T.M. Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells. Biochim Biophys Acta (BBA) - Biomembranes 2001, 1515(2):144-158.
12. Kirchmeier M.J., Ishida T., Chevrette J., Allen T.M. Correlations between the rate of intracellular release of endocytosed liposomal doxorubicin and cytotoxicity as determined by a new assay. J Lipid Res 2001, 11(1):15-29.
13. Yatvin M.B., Kreutz W., Horwitz B.A., Shinitzky M. pH-sensitive liposomes: possible clinical implications. Science 1980, 210(4475):1253-1255.
14. Needham D., Dewhirst M.W. The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv Drug Deliv Rev 2001, 53(3):285-305.
15. Yuan F., Leunig M., Huang S.K., Berk D.A., Papahadjopoulos D., Jain R.K. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 1994, 54:3352-3356.
16. Kostarelos K., Emfietzoglou D., Papakostas A., Yang W.H., Ballangrud A.M., Sgouros G. Engineering lipid vesicles of enhanced intratumoral transport capabilities: correlating liposome characteristics with penetration into human prostate tumor spheroids. J Liposome Res 2005, 15:15-27.
17. Therapeutic applications of Monte Carlo calculations in nuclear medicine 2003, IOP, Bristol. H. Zaidi, G. Sgouros (Eds.).
18. Thurber G.M., Schmidt M.M., Wittrup K.D. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev 2008, 60(12):1421-1434.
19. Thurber G.M., Zajic S.C., Wittrup K.D. Theoretic criteria for antibody penetration into solid tumors and micrometastases. J Nucl Med 2007, 48(6):995-999.
20. Bajagur Kempegowda G., Karve S., Bandekar A., Adhikari A., Khaimchayev T., Sofou S. pH-dependent formation of lipid heterogeneities controls surface topography and binding reactivity in functionalized bilayers. Langmuir 2009, 25:8144-8151.
21. Karve S., Bajagur Kempegowda G., Sofou S. Heterogeneous domains and membrane permeability in phosphatidylcholine-phosphatidic acid rigid vesicles as a function of pH and lipid chain mismatch. Langmuir 2008, 24:5679-5688.
22. Vaupel P., Kallinowski F., Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989, 49(23):6449-6465.
23. 2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 1997, 3:177-182.
24. Boggs J.M. Lipid intermolecular hydrogen bonding: influence on structural organization and membrane function. Biochim Biophys Acta 1987, 906:353-404.
25. Mellman I. The importance of being acid: the role of acidification in intracellular membrane traffic. J Exp Biol 1992, 172(1):39-45.
26. Sofou S. Surface-active liposomes for targeted cancer therapy. Nanomedicine 2007, 2:711-724.
27. Karve S., Alaouie A., Zhou Y., Rotolo J., Sofou S. The use of pH-triggered leaky heterogeneities on rigid lipid bilayers to improve intracellular trafficking and therapeutic potential of targeted liposomal immunochemotherapy. Biomaterials 2009, 30:6055-6064.
28. Haran G., Cohen R., Bar L.K., Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1993, 1151:201-215.
29. Allen C., Dos Santos N., Gallagher R., Chiu G.N.C., Shu Y., Li W.M., et al. Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol). Biosci Rep 2002, 22:225-250.
30. Lewis G.D., Figari I., Fendly B., Wong W.L., Carter P., Gorman C., et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 1993, 37:255-263.
31. Savellano M.D., Pogue B.W., Hoopes P.J., Vitetta E.S., Paulsen K.D. Multiepitope HER2 targeting enhances photoimmunotherapy of HER2-overexpressing cancer cells with pyropheophorbide - a immunoconjugates. Cancer Res 2005, 65(14):6371-6379.
32. McIntyre J.C., Sleight R.G. Fluorescence assay for phospholipid membrane asymmetry. Biochemistry 1991, 30:11819-11827.
33. Carruthers A., Melchior D.L. Study of the relationship between bilayer water permeability and bilayer physical state. Biochemistry 1983, 22:5797-5807.
34. Tokutomi S., Ohki K., Ohnishi S.I. Proton-induced phase separation in phosphatidylserine/phosphatidylcholine membranes. Biochim Biophys Acta 1980, 596:192-200.
35. de Gennes P.G. Conformations of polymers attached to an interface. Macromolecules 1980, 13:1069-1075.
36. Marsh D., Bartucci R., Sportelli L. Lipid membranes with grafted polymers: physicochemical aspects. Biochim Biophys Acta 2003, 1615:33-59.
37. Noguchi Y., Wu J., Duncan R., Strohalm J., Ulbrich K., Akaike T., et al. Early phase tumor accumulation of macromolecules: a great difference between the tumor vs. normal tissue in their clearance rate. Jpn J Cancer Res 1998, 89:307-314.
38. Hobbs S.K., Monsky W.L., Yuan F., Roberts W.G., Griffith L., Torchilin V.P., et al. Regulation of transport pathways in tumor vessels: ROLE of tumor type and microenvironment. PNAS 1998, 95:4607-4612.
39. Jain R.K., Munn L.L., Fukumura D. Dissecting tumor pathophysiology using intravital microscopy. Nat Rev Cancer 2002, 2:266-276.